All In Biotech

Free tool

FAERS Monitor: Halaven

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 201532 or its brand name (Halaven, Eribulin Mesylate). Reports on generic versions are filed under their own applications.

Reports

3,739

Serious

3,465

93% of reports

Hospitalization

1,962

Death reported

663

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • neutropenia538
  • malignant neoplasm progression383
  • febrile neutropenia331
  • myelosuppression318
  • pyrexia216
  • neuropathy peripheral214
  • leukopenia208
  • interstitial lung disease181
  • white blood cell count decreased177
  • neutrophil count decreased171
  • fatigue159
  • nausea157
  • asthenia133
  • pneumonia121
  • decreased appetite116

Reports by year received

View as table
YearReports
20101
201174
2012247
2013213
2014161
2015334
2016383
2017354
2018281
2019255
2020196
2021243
2022273
2023337
2024189
2025120
202678

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,420 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myelosuppressionSignal31850.145.115,144
febrile neutropeniaSignal33128.225.48,643
neutrophil count decreasedSignal17123.720.53,686
leukopeniaSignal20823.520.64,447
neutropeniaSignal53822.320.710,975
malignant neoplasm progressionSignal38321.119.27,327
interstitial lung diseaseSignal18121.118.33,441
neuropathy peripheralSignal21412.711.12,296
white blood cell count decreasedSignal1779.28.01,290
pyrexiaSignal2163.53.1392
decreased appetiteSignal1162.82.3135
pneumoniaSignal1212.11.870
asthenia1332.01.766
fatigue1591.11.03
nausea1571.11.02

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.